The company Postgraduate Institute of Medical Education and Research is enrolling patients into the clinical trial investigating Amphotericin Versus Posaconazole for Pulmonary Mucormycosis.
Pulmonary mucormycosis is a serious illness with high morbidity and mortality (approximately 57%). Surgery and antifungal therapy are central in the management of mucormycosis. Unlike rhino-orbital mucormycosis, surgery is not feasible in several patients with pulmonary mucormycosis. Hence, treatment is primarily with antifungal therapy. Amphotericin B is the standard of care in the medical management of mucormycosis. However, amphotericin B is expensive, has significant adverse events, and is available only in parenteral formulation. Posaconazole is effective against Mucorales, and is currently approved for salvage therapy of mucormycosis. Recent evidence suggest that in several patients, posaconazole may be effective as a monotherapy upfront. In the current study posaconazole versus amphotericin B will be evaluated for the management of pulmonary mucormycosis in a randomized clinical trial.
The trial is designed to enroll male and female 13 Years and older and is being conducted in the Postgraduate Institute of Medical Education and Research, Chandigarh, India.
The study start date is July 1, 2022.
This page provides a more detailed overview of this clinical trial:https://ichgcp.net/clinical-trials-registry/NCT05468372